ARROW trial, Genentech, NSCLC, pralsetinib
Pralsetinib is approved by the FDA for non-small cell lung cancer with RET gene fusions
August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), as determined by an FDA..